• Tyme to Present at Biotech Showcase™ 2018

    Source: Nasdaq GlobeNewswire / 13 Dec 2017 12:00:10   America/New_York

    NEW YORK, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Tyme Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that management will present a company overview at the Biotech Showcase™ 2018, to be held Jan. 8-10, 2018.

    Biotech Showcase 2018
    Location: San Francisco, Calif.
    Presentation date / time: Wednesday, Jan. 10, 2018, 4:30 p.m. PST

    About Tyme

    Tyme Inc. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. Tyme’s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and the Company is preparing to initiate an additional Phase II clinical trial in pancreatic cancer.

    For more information about Tyme, visit www.tymeinc.com.

    Contacts

    Tyme Inc.
    Jonathan Eckard
    Chief Scientific Affairs Officer
    jon.eckard@tymeinc.com

    ICR Healthcare
    Investors
    Stephanie Carrington
    Stephanie.Carrington@icrinc.com
    646-277-1282

    6 Degrees
    Media
    Sarah Hall
    shall@6degreespr.com
    215-313-5638

    Primary Logo

Share on